|
|
Marketing Authorisations
|
|
|
|
|
A drug that should never have been authorised
|
|
|
|
|
|
|
|
|
|
|
|
No proof of efficacy and adverse effects still insufficiently known
|
|
|
|
|
|
|
|
|
|
Inadequate premarketing assessment
|
|
|
|
|
|
|
|
|
|
An option after failure of platinum-based chemotherapy
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Little benefit, documented harms and many uncertainties regarding long-term use
|
|
|
|
|
|
|
|
|
|
|
|